TICKERNERD
Menu
PTCTPTCTHealthcare · Biotechnology

PTCT Stock Forecast: PTC Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Aug 2026
$73
−0.34% on the day

The 14 Wall Street analysts covering PTC Therapeutics, Inc. hold a median 12-month price target of $100 — +37.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 17 Aug 2026 — in the upper half.

Market cap
$6.1B
Ticker Nerd rank
66 / 100
Median analyst target
$100
Analysts covering
14
Total return, dividends reinvested
1W
−1.5%
1M
−7.6%
YTD
−4.4%
1Y
+45.8%
From 52W high
−18.9%
From 52W low
+48.7%
$49
$90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PTCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PTC Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Aug 2026
66 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
96
Value
95
Revisions
84
Momentum
80
Volatility
73
Accruals
31
Size
22
Growth
18
Issuance
18

Quality (96): The business earns solid, repeatable profits on what it owns.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PTCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PTCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26PTCTHigh $130Median $100Low $70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
11 Buy2 Hold1 Sell
Low $70Median $100High $130

The green dot is the last close — the median target sits +37.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
14 Aug 2026BarclaysMaintainsOverweight$120 → $122
13 Aug 2026Wells FargoMaintainsOverweight$106 → $109
31 July 2026Morgan StanleyMaintainsOverweight—
31 July 2026Morgan StanleyMaintainsOverweight$93 → $104
31 July 2026Wells FargoMaintainsOverweight—
31 July 2026Wells FargoMaintainsOverweight$93 → $106
20 July 2026Wells FargoMaintainsOverweight$95 → $93
20 July 2026Wells FargoMaintainsOverweight—
16 July 2026Cantor FitzgeraldMaintainsOverweight$124 → $130
16 July 2026Cantor FitzgeraldMaintainsOverweight—
7 July 2026RBC CapitalMaintainsSector Perform—
9 June 2026CitigroupAssumesBuy$75 → $108
27 May 2026JefferiesUpgradeBuy—
8 May 2026RBC CapitalMaintainsSector Perform—
8 May 2026TD CowenUpgradeBuy—
8 May 2026Wells FargoMaintainsOverweight—
30 Mar 2026JefferiesDowngradeHold—
23 Feb 2026Morgan StanleyMaintainsOverweight—
20 Feb 2026B of A SecuritiesMaintainsBuy—
20 Feb 2026RBC CapitalMaintainsSector Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PTCT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PTCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+21.6%
Analysts raising
2
Analysts cutting
0
Fundamentals

PTC Therapeutics, Inc. (PTCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.5×

Cheaper than 63% of US stocks

Price / sales
6.0×

Cheaper than 22% of US stocks

Price / book
−36.6×

Cheaper than 99% of US stocks

EV / EBITDA
40.1×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
101.5%

Higher than 93% of US stocks

Earnings growth (YoY)
101.5%

Higher than 84% of US stocks

Gross margin
94.5%

Higher than 98% of US stocks

Operating margin
41.3%

Higher than 92% of US stocks

Net margin
−3.8%

Higher than 25% of US stocks

Returns & dividend
Return on equity
−332.5%

Higher than 5% of US stocks

Return on assets
2.5%

Higher than 62% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PTCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PTCTPTC Therapeutics, Inc.$6.1B
66
TVTXTravere Therapeutics, Inc.$6.0B
84
CAICaris Life Sciences, Inc.$6.1B
32
XENEXenon Pharmaceuticals, Inc.$6.0B
50
DFTXDefinium Therapeutics, Inc.$5.9B
38
DNTHDianthus Therapeutics, Inc.$6.3B
61
ERASErasca, Inc.$6.3B
58

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PTC Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PTCT news & analysis

PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal

MarketBeat · 16 Aug 2026positive

PTC Therapeutics plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction in a $111 million deal. The acquisition would add a potential one-time treatment to the company's rare disease portfolio, leveraging its existing global commercial and regulatory infrastructure.

Why it matters — PTCT watchers would care because this deal could expand the company's rare disease pipeline with a potential one-time gene therapy treatment while capitalizing on its established commercial and regulatory infrastructure.

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'

Benzinga · 13 Aug 2026positive

PTC Therapeutics announced it is expanding its rare disease portfolio by planning to acquire the ST-920 Fabry disease program from Sangamo Therapeutics through a competitive bankruptcy auction. The company described the move as a "unique opportunity."

Why it matters — A PTCT watcher would care because the acquisition would add a Fabry disease program to the company's rare disease pipeline.

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript

Seeking Alpha · 13 Aug 2026neutral

PTC Therapeutics discussed its acquisition of the ST-920 Fabry gene therapy asset and shared related clinical data from the STAAR study during a transcript-covered discussion. The company addressed the details of the acquisition and the study results.

Why it matters — A PTCT watcher would care because the ST-920 acquisition and STAAR study data relate directly to the company's gene therapy pipeline for Fabry disease.

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PRNewsWire · 12 Aug 2026positive

PTC Therapeutics announced a planned acquisition of ST-920, a BLA-stage AAV gene therapy for Fabry disease, which would expand its rare disease portfolio. The company expects to complete the BLA submission in Q4 2026 with a potential commercial launch in 2027, and will host a conference call on Aug. 12 at 5 p.m. ET.

Why it matters — PTCT watchers would care because the acquisition adds a late-stage, one-time administered gene therapy to PTC's rare disease pipeline and leverages its existing regulatory, commercial, and Fabry therapy experience.

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research · 4 Aug 2026positive

PTC Therapeutics (PTCT) is described as technically oversold after losing 20.3% over four weeks, with heavy selling pressure possibly exhausted. Strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Why it matters — A PTCT watcher would care because oversold conditions combined with rising analyst earnings estimates may signal that the stock's recent slide could be approaching a turnaround.

FAQ

Frequently asked questions about PTCT stock

What is the PTCT stock price forecast for 2026-2027?

The 14 Wall Street analysts covering PTC Therapeutics, Inc. have a median 12-month price target of $100, with estimates ranging from $70 to $130. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PTCT stock a buy right now?

Of the 14 analysts covering PTC Therapeutics, Inc., 11 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks PTC Therapeutics, Inc. 66 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PTCT?

As at 17 Aug 2026, PTC Therapeutics, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).

Will PTCT stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +37.7% from the last close, and Ticker Nerd's factor model ranks PTC Therapeutics, Inc. 66 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PTCT stock forecast for 2030?

No analyst covering PTC Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $130 over the next 12 months.

How has PTCT stock performed over the past year?

PTC Therapeutics, Inc. returned +45.8% over the 12 months to 18 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PTC Therapeutics, Inc. do?

PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for people living with rare and serious disorders.

What is the latest news on PTCT?

The most recent item we track (MarketBeat, 16 Aug 2026): "PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal". PTC Therapeutics plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction in a $111 million deal. The acquisition would add a potential one-time treatment to the company's rare disease portfolio, leveraging its existing global commercial and regulatory infrastructure.

Company

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for people living with rare and serious disorders. The company’s current portfolio centers on treatments for neurology and metabolism-related rare diseases, with approved therapies and additional product candidates spanning discovery, research, and clinical development. PTC Therapeutics also operates as a global life science business, combining internal research capabilities with commercialization expertise to support patients across children and adults. Its work is concentrated on clinically differentiated medicines aimed at addressing high unmet medical needs in specialized therapeutic areas. Based in Warren, New Jersey, PTC Therapeutics plays a meaningful role in the rare disease market through its diversified product pipeline and commercial operations.

CEO Dr. Matthew B. Klein F.A.C.S., M.D., M.S. · 991 employees · United States · https://www.ptcbio.com